Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001216433 | SCV001388230 | uncertain significance | Spermatogenic failure 18; Ciliary dyskinesia, primary, 37 | 2022-10-18 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 2622 of the DNAH1 protein (p.Arg2622Gln). This variant is present in population databases (rs200587980, gnomAD 0.06%). This variant has not been reported in the literature in individuals affected with DNAH1-related conditions. ClinVar contains an entry for this variant (Variation ID: 945725). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DNAH1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004033997 | SCV003870023 | uncertain significance | not specified | 2023-02-17 | criteria provided, single submitter | clinical testing | The c.7865G>A (p.R2622Q) alteration is located in exon 50 (coding exon 49) of the DNAH1 gene. This alteration results from a G to A substitution at nucleotide position 7865, causing the arginine (R) at amino acid position 2622 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV003481000 | SCV004226119 | uncertain significance | not provided | 2023-01-31 | criteria provided, single submitter | clinical testing |